Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study.
The incidence of non-Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20- to 24-year-olds. Very elderly patients are often not treated with standard immunochemotherapy because of poor performance status, comorbidities, and toxicity concerns. We retrospectively analyzed data for 29 patients diagnosed with diffuse large B-cell lymphoma or grade 3B follicular lymphoma and treated with rituximab in combination with nonpegylated liposomal doxorubicin between January 2010 and August 2015. The median age was 84 years. The overall 3-year survival, cause-specific survival, and progression-free survival rates were 46%, 55%, and 44%, respectively. Among prognostic factors, only the achievement of complete remission strongly correlated with overall survival, cause-specific survival, and progression-free survival rates. Treatment caused very mild toxicity, without treatment-related hospitalization or toxic deaths.
Center for the Diagnosis and Treatment of Lymphomas, Department of Hematology, Transfusion Medicine and Biotechnology, Spirito Santo Hospital, Pescara, Italy.
Giuseppina
http://orcid.org/0000-0002-1963-6311
G
Ricciuti
Center for the Diagnosis and Treatment of Lymphomas, Department of Hematology, Transfusion Medicine and Biotechnology, Spirito Santo Hospital, Pescara, Italy.
Erica
E
Finolezzi
Center for the Diagnosis and Treatment of Lymphomas, Department of Hematology, Transfusion Medicine and Biotechnology, Spirito Santo Hospital, Pescara, Italy.
Stefania
S
Luciani
Center for the Diagnosis and Treatment of Lymphomas, Department of Hematology, Transfusion Medicine and Biotechnology, Spirito Santo Hospital, Pescara, Italy.
Elena
E
Ranucci
University of Modena and Reggio Emilia, Modena, Italy.
Massimo
M
Federico
Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Chieti, Italy.
Marta
M
Di Nicola
Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" University, Chieti, Italy.
Isaia Antonio Luca
IAL
Zecca
Center for the Diagnosis and Treatment of Lymphomas, Department of Hematology, Transfusion Medicine and Biotechnology, Spirito Santo Hospital, Pescara, Italy.
Francesco
F
Angrilli
D000369:Aged, 80 and over; D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab / Q000494:pharmacology / Q000627:therapeutic use*
D000074322:Antineoplastic Agents, Immunological; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D000069283:Rituximab; D004317:Doxorubicin
lymphoma; nonpegylated liposomal doxorubicin; rituximab; very elderly